Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ

Abstract

The most common cause of cancer among women is breast cancer, accounting for almost one in every ten new cases of cancer every year. Invasive lesions include ductal carcinoma (now called 'no special type' (NST)) as well as lobular carcinoma, both of which have preinvasive counterparts in the form of ductal carcinoma in situ along with lobular cancer in situ (or lobular neoplasia). DCIS normally has no outward signs or symptoms. Yet, a lump or discharge from the nipple might be observed in a few cases. Many classification systems have been created due to the microscopic heterogeneity of DCIS. This review was conducted to find out whether Tamoxifen is the ideal choice of therapy for post operative DCIS among other therapies.